Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 742 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR American tobacco company Philip Morris International offers £1bn for UK pharma... July 9, 2021 Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated... September 27, 2023 Regular Aspirin Use May Increase Older People’s Risk of Dying from... August 18, 2020 Does Living Near Power Lines Increase My Risk of Cancer? March 17, 2022 Load more HOT NEWS The UK Government’s response to Javed Khan’s tobacco review: A small... 4 Tips from Oncology Dietitians for Healthier Eating During Cancer High Frequency of Germline ATM Variants in CLL Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active...
